

Biomedical science and public health: Intersecting on the silk road



Irma E. Arispe, PhD.

Associate Director, Analysis and Epidemiology

National Center for Health Statistics

Centers for Disease Control and Prevention

Presentation to NIH SMRB, June 11, 2013



There are many pathways from research to outcome (and back)

Bench to bedside

- Data from RCTs provide evidence
- Body of evidence informs clinical recommendations; Evidence based recommendations are diffused into clinical practice
- Improved clinical practice results in better care and better outcomes

Beside to community

- Public health data captures incidence and prevalence
- Clinical performance measures capture provider actions
- Patient and population data document behavior and health status
- Multiple measures track outcomes, changes over time.



National Center for Health Statistics

What We Do:

Monitor the nation's health by collecting, analyzing and disseminating health data

- Compare across time, populations, providers and geographic areas
- Identify health problems, risk factors, and disease patterns
- Inform actions and policies to improve the health of the American people




NCHS Data Collection Systems and Surveys Use These Sources ...

- **Birth and death records** (National Vital Statistics System)
- **Personal interviews** in the home and via phone (National Health Interview Survey, National Survey of Family Growth, State and Local Area Integrated Telephone Survey)
- **Physical examinations and laboratory testing** in mobile exam centers (National Health and Nutrition Examination Survey)
- **Medical records** from hospitals, emergency rooms, outpatient clinics, physicians' offices, nursing homes and hospice and home care agencies (National Health Care Surveys)
- **Interviews with health care providers** in hospitals, physicians' offices and long term care agencies (National Health Care Surveys)




Age-adjusted death rates for selected causes of death for all ages, by sex: United States, 2000–2010



SOURCE: CDC/NCHS, *Health, United States*. Data from the National Vital Statistics System.




Number of Deaths Due to Heart Disease and Cancer: United States, 1950-2015



NOTE: Data for 2011 are preliminary data from the National Vital Statistics System. Data for 2012-2015 are based on a simple linear projection of data for 2008-2011.




High serum total cholesterol and use of cholesterol-lowering drugs: 1988-1994 through 2007-2010



SOURCE: CDC/NCHS, *Health, United States*. Data from the National Health and Nutrition Examination Survey.



Trends in estrogen/progestin drug mention population rates at physician office visits by patient's age: United States, 1995-2003




NOTES: Rates based on visits made by females. Trend for 65 years and over 1995-2000 is significant. All trends for 2001-2003 are significant ($p < 0.05$). Rate computed with revised 2001-03 weight indicated by dotted line; original weight indicated by solid line. The revised weight includes adjustment for variation in the typical number of weeks worked annually and for variation in visit volume in a work week, whereas the weights for 2000 and earlier do not.



3. Evaluating Folic Acid Fortification

- FDA regulation to fortify grain products with folic acid (1998)
- NHANES data pre- and post- fortification showed increased blood folate levels in young women
- Vital Statistics data showed ultimate impact with declines in Spina Bifida rates
- Continuing data collection allows evaluation of fortification policy safety




10. Tracking Hypertension



- Used to track hypertension prevalence by Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure since 1980
 - Decline between 1976-80 and 1988-1994
 - Increase between 1988-94 and 1999-2000
- Since 1988-94 interview plus measured blood pressure data allow estimation of awareness, treatment, and control of hypertension

Figure 4. Awareness of hypertension among hypertensives adults: United States, 2005-2006



Measured blood pressure

women

men

1960-62

1971-74


1976-80

1988-94

1999-02


22. Elucidating Exposure to Second Hand Smoke (SHS) & Monitoring Reduction Policies

- 1st measured biological assessment of SHS in US (NHANES III)
- Documented widespread SHS exposure – 84% of non-smokers
- Trend analysis showed decline of 45% among nonsmokers between 1988-94 and 1999-2004



Monitoring the effects of health care policy changes


Percentage of Office-based Physicians with Electronic Medical Records



Source: National Ambulatory Medical Care Survey



Health Insurance Coverage, Ages 19–25



Source: National Health Interview Survey

NIH and NCHS partnerships

- **Collaborators** on NCHS surveys (e.g., NHANES, NHIS cancer supplement)
- **Methodological partnerships** (National Children's Study)

- **Healthy People workgroups**
 - Objective, target setting
 - Examples include heart disease and stroke, asthma, oral health, and others

- **National reporting efforts**

- Health US
- Aging Forum, Children's Forum



New intersections, new partnership opportunities

Vital statistics

- Electronic birth and death records

Health Care


- Expansions in sample size yield state estimates
- New clinical data for EB preventive services

NHANES

- 24-hour urine collection pilot
- Health Measures at home (with NHIS)
- DNA bank

NHIS

- New LBGT data
- More state level estimates





- Linked data enable broader analyses of factors that influence health and health outcomes.
- Surveys are linked with administrative data such as
 - The National Death Index;
 - Claims data from the Centers from Medicare & Medicaid Services; and
 - Supplemental Security Income data from the Social Security Administration
- Linked data are accessed through
 - Public use files
 - the NCHS Research Data Center (for restricted use files)
- OAE conducts research on linkage methods, analytic methods for using the data, and on health and health policy issues.



NCHS Research Data Center

- Provides a mechanism for researchers to access data not released to the public because of nondisclosure or confidentiality reasons
 - Small area or micro data
 - Matches/ links to external data files
- Access is provided either on site or via a remote system
- Plans for an RDC in HHH building



Visit our website at <http://www.cdc.gov/nchs>

U.S. STANDARD CERTIFICATE OF LIVE BIRTH			
LOCAL FILE NO.		BIRTH NUMBER:	
C H I L D	1. CHILD'S NAME (First, Middle, Last, Suffix)	2. TIME OF BIRTH (24 hr)	3. SEX
	4. DATE OF BIRTH (Mo/Day/Yr)		
M O T H E R	5. FACILITY NAME (If not institution, give street and number)	6. CITY, TOWN, OR LOCATION OF BIRTH	7. COUNTY OF BIRTH
	8a. MOTHER'S CURRENT LEGAL NAME (First, Middle, Last, Suffix)	8b. DATE OF BIRTH (Mo/Day/Yr)	
	8c. MOTHER'S NAME PRIOR TO FIRST MARRIAGE (First, Middle, Last, Suffix)	8d. BIRTHPLACE (State, Territory, or Foreign Country)	
	9a. RESIDENCE OF MOTHER-STATE	9b. COUNTY	9c. CITY, TOWN, OR LOCATION
F A T H E R	10a. FATHER'S CURRENT LEGAL NAME (First, Middle, Last, Suffix)	10b. DATE OF BIRTH (Mo/Day/Yr)	10c. BIRTHPLACE (State, Territory, or Foreign Country)
C E R T I F I E R	11. CERTIFIER'S NAME: _____	12. DATE CERTIFIED	13. DATE FILED BY REGISTRAR
	TITLE: <input type="checkbox"/> MD <input type="checkbox"/> DO <input type="checkbox"/> HOSPITAL ADMIN. <input type="checkbox"/> CNM/CM <input type="checkbox"/> OTHER MIDWIFE	MM / DD / YYYY	MM / DD / YYYY



NIH SCIENTIFIC MANAGEMENT REVIEW BOARD
VALUE OF BIOMEDICAL RESEARCH

June 4-5, 2013
Bethesda, Maryland

James W. Curran, MD, MPH
Rollins School of Public Health
Emory University



Public Health

“is what we, as a society, do
collectively to assure conditions
in which people can be healthy...”

Institute of Medicine, 1987



Public Health

Focus in on health of populations.

Focus is on prevention.

Main functions are: Assessment (data)
 Policy Development
 Assurance




Public Health

Priority setting:

- 1) Numbers of persons in a population affected (or potentially affected);
- 2) Severity of conditions;
- 3) Ability to impact (1) and/or (2).



Research Spectrum



Research Priorities vs. Public Health Priorities

- 1) Research progress not always linear;
- 2) Opportunities for success may differ;
- 3) Time lag from research finding to implementation on wide scale;
- 4) Political considerations.

Attributing Research Success in Public Health

- 1) Existing data sets may be inadequate:
 - a) focus on disease, biomarkers, less than prevention;
 - b) time lags between research and implementation;
 - c) sampling may not match populations with greatest potential impact (size, focus);
 - d) specialized data needs should be specified and supported early.



Attributing Research Success in Public Health

- 2) Research is often collaborative in sponsorship;
- 3) Success (or failure) in improving health is often multifactorial;
- 4) Social determinants of health often ignored by policy makers (and researchers).



Examples from HIV/AIDS:

- 1) Multidisciplinary collaborations
- 2) Research
 - NIH
 - Other USG Agencies
 - Industry
 - Foundations



Examples from HIV/AIDS:

- 3) Breakthroughs
 - Problem definition
 - Etiology
 - Therapy
 - Impact on populations
- 4) Data availability for public health:
 - best in US / developed countries;
 - best for treatment / mortality;
 - less adequate – prevention, developing countries.





CAROLINA
A RESEARCH UNIVERSITY

Barbara Entwisle, PhD
*Vice Chancellor for Research
Kenan Distinguished Professor
(Sociology, Geography, Ecology)*

June 4, 2013



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

NIH Mission

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to **enhance health, lengthen life, and reduce illness and disability.**

The goals of the agency are:

- to foster fundamental creative discoveries, innovative research strategies, and their applications as a basis for ultimately protecting and improving health;
- to develop, maintain, and renew scientific human and physical resources that will ensure the Nation's capability to prevent disease;
- to expand the knowledge base in medical and associated sciences in order to enhance the Nation's economic well-being and ensure a continued high return on the public investment in research; and
- to exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science.

<http://www.nih.gov/about/mission.htm>



UNC
RESEARCH

NIH Impact Statement

Our Health

Over the years, our nation has made impressive gains in health and longevity. A driving force behind that progress has been medical research supported by NIH.



Thanks in large part to NIH research, [Americans are living nearly 30 years longer than they did in 1900](#). Not only have these gains in longevity enriched many lives, they have added an estimated \$3.2 trillion annually to the U.S. economy since 1970.

What's more, Americans are not just living longer, they are staying active longer. In the last 25 years,


[the proportion of older people with chronic disabilities has dropped by nearly one-third](#).

Such progress is made possible by NIH's support of many different types of research focused on a wide range of conditions. Here's an overview of a few of the major health advances fueled by NIH-funded research.

<http://www.nih.gov/about/impact/health.htm>




Age adjusted death rate for multiple causes and NIH funds, United States, 1938–2004.



Manton K G et al. PNAS 2009;106:10981-10986




Age-adjusted death rates as a function of 10-year lagged NIH funds average.



Manton K G et al. PNAS 2009;106:10981-10986




UNC
RESEARCH



Manton K G et al. PNAS 2009;106:10981-10986



UNC
RESEARCH




NIH funding trajectories and their correlations with US health dynamics, 1950-2004

Deaths (million) avoided by NIH funding

Year	Observed	Avoided	
		Total	Annual
1950-1969*	47.3	1.2	0.06
1970-1989	47.5	14.2	0.71
1990-1997	19.2	9.4	1.18
1998-2004	17.0	10.3	1.47
1950-2004	130.9	35.2	0.64

Manton K G et al. PNAS 2009;106:10981-10986

The Impact of NIH Funding on Health and Longevity



"I THINK YOU SHOULD BE MORE EXPLICIT HERE IN STEP TWO."

NIH Mission

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

The goals of the agency are:


- to foster fundamental **creative discoveries, innovative research strategies**, and their **applications** as a basis for ultimately protecting and improving health;
- to **develop**, maintain, and renew scientific **human** and physical **resources** that will ensure the Nation's capability to prevent disease;
- to **expand the knowledge base** in medical and associated sciences in order to enhance the Nation's economic well-being and ensure a continued high return on the public investment in research; and
- to exemplify and promote the highest level of scientific integrity, **public accountability**, and social responsibility in the conduct of science.

<http://www.nih.gov/about/mission.htm>



UNC
RESEARCH

A People Centered Approach



Source: Ian Foster, University of Chicago



UNC
RESEARCH


Social Networks and the Creation, Dissemination, and Application of New Ideas

- Explicit project-based collaborations
- Flows of research materials
- Flows of students/postdocs
- Shared data sets
- Spatially organized "collisions"
- Overlapping panel membership
- Other personal contacts

Owen-Smith and Levenstein. 2013. "Assessing the Social and Economic Roles of Research Universities." Measuring the Results of Research Investments, University of Chicago.



UNC
RESEARCH



National Longitudinal Study of Adolescent Health



Add Health

Social, Behavioral, and Biological Linkages Across the Life Course

The National Longitudinal Study of Adolescent Health (Add Health) is a longitudinal study of a nationally representative sample of adolescents in grades 7-12 in the United States during the 1994-95 school year. The Add Health cohort has been followed into young adulthood with four in-home interviews, the most recent in 2008, when the sample was aged 24-32*. Add Health combines longitudinal survey data on respondents' social, economic, psychological and physical well-being with

contextual data on the family, neighborhood, community, school, friendships, peer groups, and romantic relationships, providing unique opportunities to study how social environments and behaviors in adolescence are linked to health and achievement outcomes in young adulthood. The fourth wave of interviews expanded the collection of biological data in Add Health to understand the social, behavioral, and biological linkages in health trajectories as the Add Health cohort ages through adulthood.



<http://www.cpc.unc.edu/projects/addhealth>



UNC
RESEARCH

Add Health: Contribution to Science

Add Health has become a national and global data resource for over 10,000 Add Health researchers:

Funded research grants	600+
Referee publications	2000+
Books	19
Book chapters	75
Dissertation/Theses	450+

Source: Dr. Kathleen Mullan Harris, PI



UNC
RESEARCH

Science of Science Policy Approach

- Need feasible, low cost and flexible approach, so use science to describe and to manage the scientific ecosystem.
- Conceptual framework: Science is done by scientists so focus on scientists and networks of scientists
- Empirical framework: New ways of collecting data so use new cybertools to capture information automatically
- Pragmatic Approach: New ways of presenting information to visualize information so public can see results of research



UNC
RESEARCH

The Next Step: Discovery to Impact

Dissemination: Get the message out to those who need to know.


Implementation: Transform policy, programs, practice

Commercialization: Create commercially viable drugs, devices, diagnostics



UNC
RESEARCH

Discovery to Commercialization



http://nciia.org/sites/default/files/u26/Anita_NSF%20Program%20Overviews.pdf



UNC
RESEARCH

Concluding Remarks

Measuring the impact of NIH investments on improved live expectancy is challenging

- Complex linkage between funding and health outcomes

Linking funding to projects

Linking projects to discovery:

- Projects compliment and build on each other over time
- Constructed around networks of faculty, students, postdocs, staff
- Discovery can be the product of a decade or more of work

Importance of shared infrastructure:

- Data are an important product of research
- They can be used and reused, combined and recombined over time
- Joint use creates networks of faculty, students, postdocs, staff



UNC
RESEARCH

Concluding Remarks

Linking discovery to projects:

- Knowledge builds
- Discovery can draw from disparate sources
- Can involve other non-NIH sources of funds

Linking discovery to health impact:

- Going beyond the bench
- A “hand-off” to industry, commercial interests, policy-makers, practioners, population
- Complex set of linkages, some of which are beyond NIH purview
- Takes time

Overall, need a scientific approach.



UNC
RESEARCH

+ Assessing value

- (1) Define what is “success”
- (2) Establish measures of success
- (3) Create systems and supports to measure
- (4) Collect data
- (5) Analyze progress toward success
- (6) Make adjustments, repeat



Attributing Value



Laurel L. Haak, PhD
Executive Director, ORCID
<http://orcid.org/0000-0001-5109-3700>

+ What is Failure?



Millennium Bridge was dubbed 'Wobbly Bridge' after a swaying motion led to its closure two days after opening



On 7 November 1940, the Tacoma Narrows Bridge collapsed under the force of wild oscillations caused by 40mph winds


<http://eandt.theiet.org/magazine/2012/03/a-bridge-too-far.cfm>

+ What is Success?

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

The goals of the agency are:

- to foster fundamental creative discoveries, innovative research strategies, and their applications as a basis for ultimately protecting and improving health;
- to develop, maintain, and renew scientific human and physical resources that will ensure the Nation's capability to prevent disease;
- to expand the knowledge base in medical and associated sciences in order to enhance the Nation's economic well-being and ensure a continued high return on the public investment in research; and
- to exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science.



<http://www.nih.gov>

+ What do we measure?

- (1) Creative discoveries
- (2) Innovative research strategies
- (3) Application of discoveries and strategies
- (4) Human and physical resources
- (5) Knowledge base in medical sciences
- (6) Integrity, accountability, and social responsibility

+ Logic Model




Fig. 1 Logic model of NCI K awards outcome evaluation. The logic model highlights K program inputs, activities, outcomes, and impact, as well as contextual factors. The inputs include the features (demographics) that define applicants to the NCI K program, as well as features of the K mechanisms. Activities include the actions that a funded researcher would take to further their research training and career plans, and context refers to specific features of the past and

present environment in which program participants are functioning. Outcomes include measures that might be attributed to participation in the NCI K program and are divided into three broad categories of subsequent funding, productivity, and career appointments. Impact is assessed by comparing outcomes of closely matched cohorts of K awardees and non-awardees and examining proxies of scientific research and engagement

+ Outcomes: What discoveries has NIH funded?

NIH Public Access Policy Details

The NIH Public Access Policy implements Division G, Title II, Section 218 of PL 110-161 (Consolidated Appropriations Act, 2008). The law states:

The Director of the National Institutes of Health shall require that all investigators funded by the NIH submit or have submitted for them to the National Library of Medicine's PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication: Provided, That the NIH shall implement the public access policy in a manner consistent with copyright law.

<http:///>



An **industry-wide methodology** for connecting scholarly publications to research funders

HOW FUNDREF WORKS

1. FundRef Registry provides a taxonomy of 4000 standardized funder names.
2. Manuscript tracking system vendors incorporate FundRef Registry into the publication submission processes. Publishers ask authors to select correct funders and provide grant numbers upon manuscript submission.
3. Funder information transferred to publisher production systems.
4. Publishers send funder information to CrossRef
5. Funders and others query CrossRef and receive DOIs and metadata for articles resulting from their funding.
6. Publishers may display FundRef data in CrossMark Record tab.



FundRef Workflow

<http://www.crossref.org/fundref/index.html>

Recommend: NIH should participate in FundRef and encourage participation by other funders.

+ Outcomes: What “applications of discoveries” has NIH supported?

Bayh–Dole Act

From Wikipedia, the free encyclopedia

The **Bayh–Dole Act** or **Patent and Trademark Law Amendments Act** (Pub. L. 96-517, December 12, 1980) is United States legislation dealing with intellectual property arising from federal government-funded research. Sponsored by two senators, Birch Bayh of Indiana and Bob Dole of Kansas, the Act was adopted in 1980, is codified at 94 Stat. 3015, and in 35 U.S.C. § 200-212,^[1] and is implemented by 37 C.F.R. 401.^[2]

The key change made by Bayh-Dole was in ownership of inventions made with federal funding. Before the Bayh–Dole Act, federal research funding contracts and grants obligated inventors (where ever they worked) to assign inventions they made using federal funding to the federal government.^[3] Bayh-Dole permits a university, small business, or non-profit institution to elect to pursue ownership of an invention in preference to the government.^[4]

http://en.wikipedia.org/wiki/Bayh-Dole_Act

United States Patent Distelhorst, et al.		8,445,411 May 21, 2013															
Inhibitors of BCL-2																	
<p>Abstract</p> <p>A purified polypeptide for inhibiting binding of BCL-2 to IP sub-3 receptors includes an amino acid sequence consisting of about 10 to 80 amino acids. The amino acid sequence has a sequence identity at least 90% homologous to a portion of SEQ ID NO-1. The polypeptide inhibits binding of Bcl-2 to IP sub-3 receptors of cells that express IP sub-3R and Bcl-2 and induces apoptosis in a cell.</p>																	
Inventors:	Distelhorst; Clark W. (Shaker Heights, OH); Rong; Yiping (Cleveland, OH)																
Applicants:	<table border="1"> <thead> <tr> <th>Name</th> <th>City</th> <th>State</th> <th>Country</th> <th>Type</th> </tr> </thead> <tbody> <tr> <td>Distelhorst; Clark W.</td> <td>Shaker Heights</td> <td>OH</td> <td>US</td> <td></td> </tr> <tr> <td>Rong; Yiping</td> <td>Cleveland</td> <td>OH</td> <td>US</td> <td></td> </tr> </tbody> </table>		Name	City	State	Country	Type	Distelhorst; Clark W.	Shaker Heights	OH	US		Rong; Yiping	Cleveland	OH	US	
Name	City	State	Country	Type													
Distelhorst; Clark W.	Shaker Heights	OH	US														
Rong; Yiping	Cleveland	OH	US														
Assignees:	Case Western Reserve University (Cleveland, OH)																
Appl. No.:	13/218,818																
Filed:	August 26, 2011																
<p>Government Interest</p> <p>GOVERNMENT FUNDING</p> <p>This invention was made with government support under Grant No. N01NC100108504 and N01NC1000583 awarded by National Institutes of Health. The government has certain rights in the invention.</p>																	

Welcome to iEdison

iEdison (which stands for Interagency Edison) helps government grantees and contractors comply with a federal law, the Bayh-Dole Act. Bayh-Dole regulations require that government funded inventions be reported to the federal agency who made the award.

iEdison is interagency because it provides a single interface for grantees and contractors to interact with any participating agency.

iEdison makes it easy to learn about the law and its regulations and report an invention or patent funded by any of the agencies listed on the right.

<https://e-edison.info.nih.gov/iEdison/>

Recommend: Work with USPTO to implement standards for collection of name and grant information

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HTOFF&p=1&u=%2Fnetacgi%2FPTO%2Fsearch-adv.htm&r=17&f=G&l=50&d=PTXT&S1=NIH.GOTX.&OS=govt.NIH&RS=GOVT.NIH>

+ Outcomes: Clinical trials

What is FDAAA (U.S. Public Law 110-85 or the Food and Drug Administration Amendments Act of 2007)?

On September 27, 2007, the President signed U.S. Public Law 110-85. The law includes a section on clinical trial databases (Title VIII) that expands the types of clinical trials that must be registered in ClinicalTrials.gov, increases the number of data elements that must be submitted, and also requires submission of certain results data.

http://grants.nih.gov/clinicaltrials_fdaaa/faq.htm

ClinicalTrials.gov

A service of the U.S. National Institutes of Health

ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Learn more about clinical studies and about this site, including relevant history, policies, and laws.

Find Studies | About Clinical Studies | Submit Studies | Resources | About This Site

ClinicalTrials.gov currently lists 145,913 studies with locations in all 50 states and in 185 countries.

Search for Studies

Example: "Heart attack" AND "Los Angeles"

Search

Advanced Search | See Studies by Topic | See Studies on a Map

Search Help

- How to search
- How to find results of studies
- How to read a study record

Locations of Recruiting Studies

Non-U.S. Only (50%)
U.S. Only (44%)
Both U.S. & Non-U.S. (6%)

Total N = 30,399 studies
Data as of May 24, 2013

See more trends, charts, and maps

For Patients & Families

- How to find studies
- See studies by topic
- Learn about clinical studies
- Learn more...

For Researchers

- How to submit studies
- Download content for analysis
- About the results database
- Learn more...

For Study Record Managers

- Why register?
- How to register study records
- FDAAA 801 Requirements
- Learn more...

Learn More

- ClinicalTrials.gov Online Training
- Glossary of common site terms
- For the Press
- Using our RSS Feeds

Clinical Trials

at M. D. Anderson Cancer Center

By Clinical Trials Registration Number (NCT#)

Click on blue triangle to read clinical research studies. Information is displayed as: Study Number/Treatment Agent(s) Cancer Type(s) Physician.

- NCT01592136
- NCT00003641
- NCT00003645
- NCT00003787
- NCT00003854
- NCT00003857
- NCT00004054

<http://uttm-ext01a.mdaacc.tmc.edu/dept/prof/clinicaltrials/vp/rs/NCIopenreview>

Recommend: implement standards for collection of name and grant information

<http://clinicaltrials.gov>



Outcomes: Who did NIH train?

Posted on April 11, 2013 by Sally Rockey

Taking On the Challenge of Better Biomedical Workforce Data

<http://nexus.od.nih.gov/all/2013/04/11/taking-on-the-challenge-of-better-biomedical-workforce-data/>

The primary goal of the NIH Advisory Committee to the Director (ACD) biomedical research workforce working group was the creation of pathways through undergraduate, graduate and postdoctoral training that provide excellent preparation for biomedical research careers in a timely fashion, and that ensure future US competitiveness and innovation in biomedical research. In their [report](#), the working group members described how they were "frustrated and sometimes stymied" by the quality of the data available on the biomedical research workforce, e.g., major gaps in information on the total number of individuals working as postdocs, inadequate information on postdocs who obtained degrees in other countries, and lack of systematic data on graduate students trained in labs supported by NIH research grants.

So to this end, we've been working on a number of plans to try and fill these gaps in biomedical workforce information. Here's a quick overview of the directions we are headed.

- **Identification of all NIH-supported students and postdocs**
- **Automated NRSA training tables**
- **Develop a Fed-wide researcher profile system**
- **Encourage adoption of unique persistent researcher IDs**

Big Hopes, Small Changes for Biomedical Training

http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2012_12_14/caredita1200136

By Michael Price
December 14, 2012

Tilghman, Rockey, and the others in the working group laid out several recommendations aimed at shortening and diversifying doctoral programs and postdoc positions, increasing the proportion of trainees supported by training grants and fellowships instead of research grants, collecting more data on career outcomes, improving postdoc salaries, and promoting the staff scientist career path. After the June meeting, ACD formed an implementation team, headed by Rockey, to decide which recommendations to implement, and how to do it.




Tracking NIH-funded researchers

Encourage adoption of unique persistent researcher IDs: Identifying the output of individuals with commonly occurring names is difficult. Reducing name ambiguity within and across data systems is always expensive and time consuming. It appears that an international, non-profit organization called the Open Researcher and Contributor ID ([ORCID](#)) is gaining traction. ORCID is a persistent digital identifier that can be associated with author names in publications. The ORCID system also will allow individuals to identify their research output and create a registry of IDs. SciENcv will include a utility that make it easy for users to obtain an ORCID and to link it to their publications and grants. A broadly used researcher ID also will facilitate the identification of scientific output from those who work outside federally funded research programs.

<http://nexus.od.nih.gov/all/2013/04/11/taking-on-the-challenge-of-better-biomedical-workforce-data/>

After Rockey's presentation, Tilghman remarked that although she was pleased that ACD seriously considered her report's recommendations, she "can't help but go back to [her] cynicism" about some of the language used in the implementation plans—specifically, the occurrence of words like "encourage" and "recommend." For example, she pointed to the implementation team's plan to encourage institutions to track and report the career outcomes for their students and postdocs. "This is a recommendation that's been made by every single committee, and always using the word 'encourage,'" she said. "It has been made for about 20 years and we know what the consequences of that [are]. ... Unless you have a stick, this won't happen."

+ Encourage? Require?



The image displays two screenshots. On the left is the ORCID 'SIGN IN' page, featuring fields for 'Email or ORCID' and 'Password', with a 'Sign in' button and a 'Forgot your Password?' link. On the right is the NIH ScienCV 'Edit Personal Information' form, which includes sections for 'Required Information' (First Name, Last Name, Address, City, State, Country, Postal/zip code, Email) and 'Optional Information' (ORCID). A callout box points to the ORCID field in the ScienCV form, stating 'Import information from ORCID record'. Another callout box points to the 'SIGN IN' section of the ORCID page, stating 'Link grant application to ORCID identifier'.

NIH ScienCV to pilot use of ORCID iDs this summer

Link grant application to ORCID identifier

Import information from ORCID record

13

+ Recommend: Implement ORCID

ORCID

Connecting Research
and Researchers

ORCID provides a free registry of unique and persistent researcher identifiers. ORCID serves as a switchboard to link researcher identifiers, affiliations, and research works.

- (1) Require use of ORCID IDs during the application process, link this to post-award outcomes reporting
- (2) Require use of ORCID iDs for all persons supported on a grant
- (3) Implement a workflow to post awarded grant information to a grantee's ORCID record
- (4) Implement a workflow to allow researchers to search and link ORCID iDs to NIH grants in ReReporter, and
- (5) Link and store ORCID iDs in IMPAC II PI profile records.
- (6) Encourage use of ORCID iDs by the USPTO and C.T.org



Linking the who to the what:

Attributing Value

Science, 2011 Aug 19;333(6045):1015-9. doi: 10.1126/science.1196783.

Race, ethnicity, and NIH research awards.

Ginther DK, Schaffer WT, Schnell J, Masimore B, Liu F, Haak LL, Kington R.

Department of Economics and Center for Science, Technology & Economic Policy, Institute for Policy & Social Research, University of Kansas, Lawrence, KS 66045, USA. dginther@ku.edu

Abstract

We investigated the association between a U.S. National Institutes of Health (NIH) R01 applicant's self-identified race or ethnicity and the probability of receiving an award by using data from the NIH IMPAC II grant database, the Thomson Reuters Web of Science, and other sources. Although proposals with strong priority scores were equally likely to be funded regardless of race, we find that Asians are 4 percentage points and black or African-American applicants are 13 percentage points less likely to receive NIH investigator-initiated research funding compared with whites. After controlling for the applicant's educational background, country of origin, training, previous research awards, publication record, and employer characteristics, we find that black applicants remain 10 percentage points less likely than whites to be awarded NIH research funding. Our results suggest some leverage points for policy intervention.

ADVISORY COMMITTEE TO THE DIRECTOR

Advisory Committee to the Director

Charter

Members

Meetings

Working Group Activities

Contact the ACD

Working Group on Diversity in the Biomedical Research Workforce

Working Group Reports

- Diversity in the Biomedical Research Workforce Working Group Report (PDF - 3,468KB)
- Executive Summary of the Working Group on Diversity in the Biomedical Research Workforce (PDF - 136KB)

NIH's Plan for Action:

- Evaluate current training programs
- Phase out unsuccessful programs, expand successful ones
- Increase number of early career reviewers, including those from underrepresented populations
- Examine grant review process for bias and develop interventions
- Improve support for grant applicants
- Gather expert advice on additional action steps



Summary

- Enhance existing datasets to support their use in evaluation (e.g., ensure that name and evidence information is collected in a fielded manner and exposed through public APIs)
- Work with other agencies to enhance existing datasets
- Map out program goals and clearly articulate measures
- Collect data (qual and quant) and test measures
- Use data to adjust programs



Assessing the Value of Biomedical Research: Developing Chains of Evidence

June 4, 2013

Della Hann, Ph.D.
Deputy Director
Office of Extramural Research
NIH



Setting the Stage

In FY 2009, NIH supported an estimated:

- Over 53,000 research projects/year;
- Over 313,000 research positions
- Research training on NRSA: ~16,400 positions
- Training on research grants: ~28,200 positions
- Over 6,000 research scientists in intramural program

Research Products: Reported to NIH

- Publications – most robust; coin of the realm
 - Citations in Clinical Guidelines
- Inventions, Patents and/or Licenses
- Technologies/Techniques
- Other Products, e.g., databases, animal models, instruments



National Library of Medicine
NLM



NIH National Institutes of Health
Office of Extramural Research

Office of Extramural Research

- Designs new and more efficient methods of data collection to improve the breadth and quality of information on research products and the investigators we support
 - Electronic Application Forms
 - Research Performance Progress Reports (RPPR)
 - All Personnel Reports
- Creates the tools needed to query, navigate, and synthesize these diverse data sources, facilitating analysis of NIH-funded research and its outcomes.
 - RePORTER & ExPORTER
 - RCDC
 - SciENCv
 - Commons

NIH National Institutes of Health
Office of Extramural Research

NIH OFFICE OF EXTRAMURAL RESEARCH

But is it Knowledge?


- These products can be used as “metrics of Knowledge”
- But.... How to assess the “value” of this knowledge?
- Does anyone use the Knowledge to inform/improve health?



www.8020comms.com



<http://www.sciencemag.org>





<http://blog.cunet.com/tag/albert-einstein/>



NIH National Institutes of Health
Office of Extramural Research

Diversity of Science Challenges Assessment of Value



NIH National Institutes of Health
Office of Extramural Research





Building Chains of Evidence

Vision and Brainstorming

- Evidence will differ depending on the 'product'
- For any new initiative, could develop models of probable proximal and distal evidence
- Then consider, what databases could be tapped for assessing each part of the model
- If no databases available, are there ways to create the databases?



- Office of Extramural Research can help with:
 - Designing methods to acquire relevant data
 - Creating the tools needed to query, navigate, and synthesize data
 - Analyzing the models to assess value of research



“The crucial variable in the process of turning knowledge into value is creativity.”

- John Kao

Altmetrics and Revolutions:

New metrics for a new era of Web-native Scholarship.

bit.ly/nih-smrb-altmetrics
@jasonpriem

June 5, N H SMRB VOB Mtg
Washington DC

**What you do
matters so
much.**

Communication is
the soul of
science.

Ye Olde Letter

	The Letter
tech	pen and paper
products	letter
filters	personal

In 1665 the first revolution:

Oldenburg publishes Phil. Trans; applies the best available technology (printing press) to vastly improve dissemination.

A Step Forward : the Journal

	The Letter	The Journal
tech	pen and paper	printing press
products	letter	article
filters	personal	peer-review

A second revolution is coming

	The Letter	The Journal	The DcJ
tech	pen and paper	printing press	the web
products	letter	article	everything
filters	personal	peer-review	altmetrics

But journals are already online



Your revolution is over, sir!

"The Digital Publishing Revolution Is Over"

Online journals are
paper journals
delivered by faster
horses.

**The First Revolution
promoted homogeneity of
outputs.**

The standardized article was born of
the need for industrial-scale replication
and interchangeability.


The Second Revolution will promote diversity of outputs

With publication nearly free, it becomes trivial to capture the missing pieces of the scholarly record.

**Instead of moving
paper products
faster, we can create
web-native science.**

Conversation stories analysis data

data



Submit Data Now!
See how to submit

My Account
Login or Register

Browse
Authors
Journal Title

Information
Depositing Data
Using Data
Dryad Members
Journal Archiving Policy
About Dryad
Dryad Blog

Dataset

When using this data, please cite the original article as:

Reader SM, Hager Y, Laland KN (2011) Social learning in the great tit. *Proceedings of the Royal Society B* 366(1567): 1017-1024. doi:10.1098/rspb.2010.2104

Additionally, please cite the Dryad data package as:

Reader SM, Hager Y, Laland KN (2011) Dryad dataset. doi:10.5061/dryad.t0q94

Dryad File Identifier doi:10.5061/dryad.t0q94


Description Please refer to Reader et al. (2011)

Keywords social learning, behavior, great tit

Date Deposited 2012-11-14T18:00:48Z

Scientific Names Primates

Contained in Data Package Data from: The evolution of social learning



My data [Browse](#) [Upload](#) [J. Priem](#)

Effect of i.t. administration of PD98059 on ERK phosphorylation in Vc neurons and nociceptive behavior. [Claim article](#)

A Vehicle **C** **B** PD98059 **D** **E** **F**

Mean number of all ERK+ cells (x1000) in Vc neurons (mean ± SEM)

Naive CCI

Vehicle PD98059

Mean number of all ERK+ cells (x1000) in Vc neurons (mean ± SEM)

Naive CCI

Head-withdrawal threshold (g)

Naive CCI

Head-withdrawal latency (s)

Naive CCI

Number of vocalizations (mean ± SEM)

Naive CCI

Head-withdrawal threshold (g)

Naive CCI

Published on 23 Feb 2013 - 12:41 (GMT)
Filesize is 943.04 KB

This data is part of a published article:
[Involvement of ERK Phosphorylation of Trigeminal Ganglion Subnucleus Caudalis Neurons in Thermal Hypersensitivity in Rats with Intraoral Nociceptive Injury](#)
Published by: [PLOS ONE](#)

Categories
• [Pharmacology](#)
• [Neuroscience](#)

Authors
Ryoko Suzuki
Yoshiyuki Tezuka
Masamichi Shinoda
Kazuo Shikata
Kunika Honda
Ayano Katagiri
Masaki Kiyomoto
Barry J. Sessle

analysis

earlywarning / 97 commits

file to write csv data files from cached rda data files

cboettig authored 5 days ago Latest commit b6635f2aab

R	10 months ago	avoid nans [cboettig]
data	a year ago	Merge branch 'master' of github.com:cboettig/earlywarning [cboettig]
inst	5 days ago	file to write csv data files from cached rda data files [cboettig]
man	a year ago	summary stat looping function, dependencies added [cboettig]
DESCRIPTION	8 months ago	updated description [cboettig]
NAMESPACE	a year ago	documentation etc [cboettig]
README.md	9 months ago	README file added [cboettig]

README.md

Quantifying the Detection of Early Warning Signals

This package contains the source code, analysis, and history of my research published in the Proceedings of the Royal Society Interface, *Limits to the Detection of Early Warning Signals for Critical Transitions* with Alan Hastings, May 2012. A preprint under CC-by license is freely [available from my website](#)

- Author: Carl Boettiger
- License: [CC0](#)
- [Project navigation](#)

stories

fiction:

short story, novella, novel, series, play,
film, comic book, etc, etc...

scholarship:

paper, monograph,

video, blog posts, notebooks, infographics,
slides, etc, etc

conversation

mathoverflow

Questions

Tags

Users

Badges

Unanswered

How many proofs that $\pi_n(S^n) = \mathbb{Z}$ are there?

15

☆
7

Offhand I can think of two ways in classical homotopy theory:

1. Show that $\pi_k(S^n) = 0$ for $k < n$ by deforming a map $S^k \rightarrow S^n$ to be non-surjective, then contracting it away from a point not in its image. Now use the Hurewicz theorem to show $\pi_n(S^n) = H_n(S^n) = \mathbb{Z}$, which is easy to calculate with cellular homology.
2. Use the Freudenthal suspension theorem to induct up from $\pi_1(S^1) = \mathbb{Z}$, which you can prove using (say) the universal covering space $\mathbb{R} \rightarrow S^1$.

What other ways are there to prove $\pi_n(S^n) = \mathbb{Z}$?

at.algebraic-topology homotopy-theory big-list

flag | cite

edited Feb 8 at 8:53
Ricardo Andrade

community wiki

4 this should be community wiki – Koushik Feb 8 at 0:43

A very silly option is: run an algorithm which given a simplicial decomposition of the sphere gives you the group. As algorithm exist, this is in principle viable :-). – Mariano Suárez-Alvarez Feb 8 at 2:39

3 Am I allowed to say "countably many"? :-). – Andrej Bauer Feb 8 at 11:31

1 @Tom: Is there a way to generalize that argument to $n > 2$? – Mike Shulman Feb 8 at 16:31

1 The deformation argument in (1) is superfluous. Just calculate π_1 and H_* from the cell decomposition. Then for simply connected spaces, Hurewicz shows that the minimum $i > 0$ for which $H_i \neq 0$ is the same as the minimum $i > 0$ for which $\pi_i \neq 0$, and that the groups coincide for this i . – unknown (google) Feb 9 at 21:53

show 3 more comments

3. "aps2013dc" @jasonpriem



Sue Frantz @WorthPsychTLC 1m
S.Fiske: Our person perceptions are a 2 (warm/bad intentions) x 2 (hi/lo competence at carrying out those intentions) #aps2013dc

Details

Old Strings retweeted



Geoffrey Miller @matingmind 3h
When creating a new story, dorsolateral prefrontal cortex is more active if telling the story to opposite sex - Kevin Dunbar #aps2013dc

Details

Randall Parker retweeted



Geoffrey Miller @matingmind 1d
Children's social games function mostly to learn how to play complex, differentiated roles within groups - Roy Baumeister at #aps2013dc

Details



Michael Carmichael @MDCar... 4m
Stanley Milgram's actual shock generator here at #aps2013dc in Washington DC!
pic.twitter.com/6MloFt1Yfr



Details


Example : Twitter

In one month, over 58k citations from Twitter to scholarly articles (citwaitions?)

It is like having a jury preselect what will probably interest you.. Occasionally there will be something that people will link to, and it will change what I think, or what I'm doing, or what I'm interested in.

-study participant
Priem and Costello, 2010)

Example : Twitter



Priem, Costello, and Dzuba 2011)


Web-native science
means we can start
making public, not
merely "Publishing "

Here's my journal:



Here's how I publish:

The Decoupled Journal article: a case study.




**But how do we
filter? How do
we measure?**

**Don't turn
off the taps,
Build boats.**

The old way: countin' citations

And that's awesome!



histeite example

But citations only tell part of the story

Spotting emerging
research fronts will
require tracking
"formal and
informal
communication"
(Kuhn, 1977)

Heart of scholarly
communication
is "visits, personal
contacts, and
letters." (Bernal,
1944)

"...there are
undoubtedly
highly useful
journals that are
not cited
frequently."
(Garfield, 1972)

Impact has multiple dimensions:

Audience: Scholar, public

**Engagement
type:** Views,
discussion, saves,
citation,
recommendation

Impact has multiple dimensions:

	scholarly	public
recommended		
cited		
discussed		
saved		
scholarly		

Bibliometrics measures citation

	scholarly	public
recommended		
cited	traditional citation	
discussed		
saved		
scholarly		

Altmetrics measures impact:

	scholarly	public
recommended	faculty of 1000	popular press
cited	traditional citation	wikipedia
discussed	scholarly blogs	blogs, twitter
saved	mendeley citeulike	delicious
scholarly	pdf views	html views

Bibliometrics measures
citation

altmetrics mines
impact on the
next one.

ImpactStory.

An open-source, nonprofit startup to gather and share altmetrics.

Heather Piwowar
Jason Priem



ALFRED P. SLOAN
FOUNDATION

ImpactStory. create about follow register log in **BETA** Send us your feedback!

My Collection 9 items (expand all) update json csv Tweet 0

article

Mega-phylogeny approach for comparative biology: an alternative to supertree and supermatrix approaches

(2009) Smith, Beaulieu, Donoghue *BMC Evol Biol*

Computational toxicology using the OpenTox application programming interface and Bioclipse.

(2011) Willighagen, Jelliazkova, Hardy et al. *BMC research notes*

Multistep correlations via covariance processing of COSY/GCOSY spectra: opportunities and artifacts

(2008) Martin, Hilton, Blinov et al. *Magn. Reson. Chem.*

Automated dielectric single cell spectroscopy - temperature dependence of electrorotation

(2002) Mietchen, Schnelle, Muller et al. *Journal of Physics D: Applied Physics*

Pyramid symmetry transforms: From local to global symmetry


(2007) Zavidovique, Di Gesù *Image and Vision Computing*

dataset

Data from: Data archiving is a good investment

(2011) Piwowar, Vision, Whitlock et al. *Dryad Digital Repository*


highly saved highly cited
highly recommended highly cited
discussed saved
highly saved highly discussed cited
saved
highly saved cited saved
saved cited saved
saved cited saved
highly viewed highly discussed saved
saved



Why Altmetrics?

- Faster evaluation.
- Reward broader impacts.
- Reward web-native products.
- Build web-native filters

The network is the key




Bollen, J., Van de Sompel, H., Hagberg, A., Bettencourt, L., Chute, R., Rodriguez, M. A., & Balakireva, L. (2009). Clickstream Data Yields High-Resolution Maps of Science. PLoS ONE, 4(3), e4803. doi:10.1371/journal.pone.0004803

At web scale, the value isn't in manual curation...

YAHOO!

ask these guys

It's in mining the network



The second revolution has started.

Once we have altmetric data, it's too useful to ignore; alternative filters and even certification paths based on this data will open.

As Peter Vinkler says, citation graph data is like Chekhov's gun: once on stage, it has to be fired.

A wise men, that Chekov



Thanks!

Advisors:

- Brad Hemminger,
- Todd Vision

Funders:

- Alfred P. Sloan Foundation
- DataONE
- Dryad
- National Science Foundation
- Open Society Foundations



Questions?

Jason Priem @jasonpriem, <http://jasonpriem.org>

This is a living document; if a particular version is important to you, make sure you link to that revision.



National Institutes of Health
Turning Discovery Into Health

Scientific Management Review Board

SMRB Working Group on the Value of Biomedical Research

Gail Cassell, PhD
Chair, VOBR Working Group

SMRB

VOBR WORKING GROUP June 4, 2013

Working Group Roster

NON-FEDERAL

- Gail Cassell, PhD (*Chair*)
- Norman Augustine
- Hon. Daniel Goldin
- Garry Neil, MD
- Gilbert Omenn, MD, PhD
- William Roper, MD, MPH
- Arthur Rubenstein, MBBCh

FEDERAL

- Alan Guttmacher, MD
- Richard Hodes, MD
- Stephen Katz, MD, PhD
- Griffin Rodgers, MD, MACP
- Martha Somerman, DDS, PhD

– 2 –

VOBR WORKING GROUP June 4, 2013


Working Group Activities to Date

- **July 11, 2012 (SMRB):** NIH Director issues charge to SMRB regarding assessing the value of biomedical research
- **Sept–Dec 2012:** Compilation and analysis of relevant literature; discussion of basic evaluation framework
- **January 14, 2013 (SMRB):** SMRB meeting includes panel session focused on the economic value of biomedical research; VOBR Working Group members review relevant literature
- **March 2013:** Briefings by NIH staff on data collection and analysis tools and technology transfer; draft framework for tools and metrics for assessing value
- **April 2013:** Draft outline of report; discuss types of value and major elements of charge
- **May 2013:** Prepare questions for June 4 panel discussions

– 3 –

VOBR WORKING GROUP June 4, 2013

Deliberative Process




– 4 –

VOBR WORKING GROUP June 4, 2013

Definition of Value

“Value” is often in the eye of the beholder:



What constitutes value, who makes that determination, and how can it be observed across time?

– 5 –


VOBR WORKING GROUP June 4, 2013

Three Types of Value

- NIH’s mission is to seek **fundamental knowledge** about the nature and behavior of living systems and the application of that knowledge to **enhance health, lengthen life, and reduce the burdens of illness and disability.**
- The Working Group has divided areas of biomedical research value into three streams:
 - Scientific knowledge
 - Public health
 - Broader societal impact

– 6 –

VOBR WORKING GROUP June 4, 2013



Major Elements of the Charge

1. **Principles** that should underlie assessments of value
2. Advice regarding sound **methods and strategies** for assessing value
3. Advice regarding **study questions and selection of study topics** (e.g., case studies)

*Charge Element 1: Principles***Guiding Principles, Limitations, & Caveats**

*Why does NIH need to better assess its value?
What can we accomplish with this effort?*

The SMRB is tasked with advising NIH on the objectives of value assessments and the realistic boundaries of assessing, attributing, and communicating value.

– 9 –

VOBR WORKING GROUP June 4, 2013

*Charge Element 1: Principles***Principles Underlying Value Assessment**

- Attribution
- Causality
- Precision
- Comprehensiveness
- Disclosure of assessment limitations
- Reflect values of society
- Other?

– 10 –

VOBR WORKING GROUP June 4, 2013

*Charge Element 1: Principles***Challenges with Assessing Value**

Assessing the value of biomedical research is difficult due to challenges with assigning attribution and causality.

- Multiple factors and sectors influence the **downstream effects** of NIH activities.
- It is difficult to estimate and account for the **lag time** between research and impact.
- There are myriad challenges in collecting and analyzing data that **accurately capture the outcomes** of NIH activities.

Is there anything unique for NIH, compared with other R&D agencies, in these challenges?

– 11 –

VOBR WORKING GROUP June 4, 2013

*Charge Element 1: Principles***Common Elements of Value Assessments**

- Many models for assessing value have been developed for different contexts
- It would be useful to develop a generic model that can be customized and adapted to various study questions
- Identification of the critical components of such a model should be part of the Working Group's findings



– 12 –

VOBR WORKING GROUP June 4, 2013

Charge Element 2: Methods & Strategies

Methods & Strategies

How should we measure value?

The SMRB is tasked with identifying a set of metrics and strategies (established and emerging) that are most appropriate for this task.

- 13 -

VOBR WORKING GROUP June 4, 2013

Types of Value	OUTPUTS						OUT- COMES
Science	Short-term DISCOVERY		Medium-term VALIDATION		Long-term CONSENSUS		Fundamental Scientific Knowledge
	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	
	Conference abstract presentation	NIH Research Performance Progress Report (RPPR), "Track 1" column	Patents	USPTO database (USPA and RPPORTER (linking publications to patents)), RPPR; FDA Orange Book, etc.	FDA approvals of New Drug Applications (NDAs)	FDA Orange Book	
	Primary research article	Pubmed, ISI, RPPORTER					
	Research database and repository (e.g., NCBI, HCAP)	PubMed, ISI, RPPORTER					
Public Health	APPLICATION		IMPLEMENTATION		HEALTH MEASURES		Living longer, healthier lives
	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	
	Advanced testing of evidence-based diagnostic	RPPORTER, ISI, RPPORTER, PubMed, etc.	Dissemination	FDA approvals, Industry Reports	Dissemination	FDA approvals, Industry Reports	
	Advanced testing of evidence-based therapeutic intervention	RPPORTER, ISI, RPPORTER, PubMed, etc.	Dissemination	FDA approvals, Industry Reports	Dissemination	FDA approvals, Industry Reports	
	Advanced testing of evidence-based preventive intervention and diagnostic	RPPORTER, ISI, RPPORTER, PubMed, etc.	Dissemination	FDA approvals, Industry Reports	Dissemination	FDA approvals, Industry Reports	
Broader Societal Impacts	PROXIMAL		INTERMEDIATE		DISTAL		Scientific literacy, public health, etc.
	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	
	Support government, practice, and education	NIH Research Performance Progress Report (RPPR), "Track 1" column	Support research practice activity (e.g., Blackbox, Pharma)	FDA approvals, practice, industry reports (FDA/MA, Pharma), research, etc.	Update on research of health care innovation	NIH Research Performance Progress Report (RPPR), "Track 1" column	
	Create demand for R&D	NIH Research Performance Progress Report (RPPR), "Track 1" column					
	Support academic	NIH Research Performance Progress Report (RPPR), "Track 1" column					
Broader Societal Impacts							


Types of Value	OUTPUTS			OUT-COMES
Science	Short-term DISCOVERY	Medium-term VALIDATION	Long-term CONSENSUS	Fundamental Scientific Knowledge
	Conference abstract presentation Primary research articles Research database and infrastructure (e.g., NCBI, EMBL, ENA, etc.) Development of research resources and infrastructure Researcher training and education Researcher career development and support (e.g., postdoctoral fellowships, etc.)	Patents Licenses IP transfer agreements (ITAs) Development and initial clinical testing of dx, tx, and px interventions (e.g., FDA applications and Phase I, II, and III clinical trials) Standardized research protocols Validated data repositories (e.g., NCBI, EMBL, ENA, etc.)	(Linking publications to patents); RPPRs; FDA Orange Book; iEdison USPTO database; FDA Orange Book; iEdison Consensus Development Conference and Briefing (e.g., National Toxicology Program) Book chapters Participated in consensus guidelines Systematic review/meta-analysis Guidelines transfer material (e.g., clinical trials, etc.)	
	Conference abstract presentation Primary research articles Research database and infrastructure (e.g., NCBI, EMBL, ENA, etc.) Development of research resources and infrastructure Researcher training and education Researcher career development and support (e.g., postdoctoral fellowships, etc.)	Patents Licenses IP transfer agreements (ITAs) Development and initial clinical testing of dx, tx, and px interventions (e.g., FDA applications and Phase I, II, and III clinical trials) Standardized research protocols Validated data repositories (e.g., NCBI, EMBL, ENA, etc.)	(Linking publications to patents); RPPRs; FDA Orange Book; iEdison USPTO database; FDA Orange Book; iEdison Consensus Development Conference and Briefing (e.g., National Toxicology Program) Book chapters Participated in consensus guidelines Systematic review/meta-analysis Guidelines transfer material (e.g., clinical trials, etc.)	
Public Health	APPLICATION	IMPLEMENTATION	HEALTH MEASURES	Living longer, healthier lives
	Advanced testing of evidence-based diagnostic Advanced testing of evidence-based therapeutic intervention Advanced testing of evidence-based preventive intervention and strategy Identification of evidence-based public health issues and strategies	Diagnostic market Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	FDA approvals; Industry Reports HHS dissemination and implementation activities (e.g., National Cancer Institute, etc.) Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	
	Advanced testing of evidence-based diagnostic Advanced testing of evidence-based therapeutic intervention Advanced testing of evidence-based preventive intervention and strategy Identification of evidence-based public health issues and strategies	Diagnostic market Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	FDA approvals; Industry Reports HHS dissemination and implementation activities (e.g., National Cancer Institute, etc.) Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	
Broader Societal Impacts	PROXIMAL	INTERMEDIATE	DISTAL	Scientific literacy Public health Healthcare-related cost Productivity Capacity for innovation Global R&D competitiveness Sci. diplomacy Stability
	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	
	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	

Types of Value	OUTPUTS			OUT-COMES
Science	Short-term DISCOVERY	Medium-term VALIDATION	Long-term CONSENSUS	Fundamental Scientific Knowledge
	Indicators: Measurement and assessment tools Conference abstract presentation Primary research articles Research database and infrastructure (e.g., NCBI, EMBL, ENA, etc.) Development of research resources and infrastructure Researcher training and education Researcher career development and support (e.g., postdoctoral fellowships, etc.)	Indicators: Measurement and assessment tools USPTO database; eSPA and RePORTER (linking publications to patents); RPPRs; FDA Orange Book; iEdison Licenses IP transfer agreements (MTAs) Development and initial clinical testing of dx, tx, and px interventions (e.g., FDA applications and Phase I, II, and III clinical trials) Standardized research protocols Validated data repositories (i.e., NCBI's GenBank, PDB)	Measurement and assessment tools USPTO database; eSPA and RePORTER (linking publications to patents); RPPRs; FDA Orange Book; iEdison Licenses IP transfer agreements (MTAs) Development and initial clinical testing of dx, tx, and px interventions (e.g., FDA applications and Phase I, II, and III clinical trials) Standardized research protocols Validated data repositories (i.e., NCBI's GenBank, PDB)	
	Indicators: Measurement and assessment tools Conference abstract presentation Primary research articles Research database and infrastructure (e.g., NCBI, EMBL, ENA, etc.) Development of research resources and infrastructure Researcher training and education Researcher career development and support (e.g., postdoctoral fellowships, etc.)	Indicators: Measurement and assessment tools USPTO database; eSPA and RePORTER (linking publications to patents); RPPRs; FDA Orange Book; iEdison Licenses IP transfer agreements (MTAs) Development and initial clinical testing of dx, tx, and px interventions (e.g., FDA applications and Phase I, II, and III clinical trials) Standardized research protocols Validated data repositories (i.e., NCBI's GenBank, PDB)	Measurement and assessment tools USPTO database; eSPA and RePORTER (linking publications to patents); RPPRs; FDA Orange Book; iEdison Licenses IP transfer agreements (MTAs) Development and initial clinical testing of dx, tx, and px interventions (e.g., FDA applications and Phase I, II, and III clinical trials) Standardized research protocols Validated data repositories (i.e., NCBI's GenBank, PDB)	
Public Health	APPLICATION	IMPLEMENTATION	HEALTH MEASURES	Living longer, healthier lives
	Advanced testing of evidence-based diagnostic Advanced testing of evidence-based therapeutic intervention Advanced testing of evidence-based preventive intervention and strategy Identification of evidence-based public health issues and strategies	Diagnostic market Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	FDA approvals; Industry Reports HHS dissemination and implementation activities (e.g., National Cancer Institute, etc.) Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	
	Advanced testing of evidence-based diagnostic Advanced testing of evidence-based therapeutic intervention Advanced testing of evidence-based preventive intervention and strategy Identification of evidence-based public health issues and strategies	Diagnostic market Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	FDA approvals; Industry Reports HHS dissemination and implementation activities (e.g., National Cancer Institute, etc.) Dissemination and implementation efforts Practice guidelines, etc. Adoption of evidence-based dx, tx, and px Public health campaigns	
Broader Societal Impacts	PROXIMAL	INTERMEDIATE	DISTAL	Scientific literacy Public health Healthcare-related cost Productivity Capacity for innovation Global R&D competitiveness Sci. diplomacy Stability
	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	
	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	Support research and innovation, and education Create demand for R&D International collaboration Support academic Develop pre-competitive research Create research collaboration	

Types of Value	Types of Studies		Types of Outputs		Types of Impacts	
	Short-term DISCOVERY	Medium-term VALIDATION	Long-term CONSENSUS			
Types of Value	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools
	Conference abstract presentation	NIH/NIH-like Performance Review Program (RFPs), <i>Tool/Innovation</i>	Patient	USPTO Abstracts, FDA on RPORTER (linking publications to patents), RFPs; FDA Orange Book, etc.	FDA approvals of New Drug Applications (NDAs)	
	Primary research article	PubMed, EMBASE, ISI, SPIRIS, RPORTER, RFPs, etc.	Litigator	USPTO Abstracts, FDA Orange Book, etc.	Commercial Development Conference on Biologics (i.e., Relation of Technology Progress)	
	Research database and repository (e.g., NCBI, NIH)	<i>Individual scientific data, comprehensive tool</i>	If transfer appropriate (ITAs)	Individual University, Biotech, Database (e.g., <i>for open access data, comprehensive tool</i>)	Biologics chapter	
Types of Studies	Development of research resources and infrastructure	Review and infrastructure grants; RFPs	Development on federal clinical trials of drugs; open international (e.g., FDA application in Phase I/II, and clinical trials)	Open-source development of RFPs, etc.	Participated in curriculum development	
	Research resource research funding and reporting (e.g., self-identification, biobanks, data banks)	RFPs (self-reporting, biobanks, self-identification, etc.); <i>Tool/Innovation (e.g., open access data, comprehensive tool)</i>	Standardized research protocols	<i>Publication database, formal comprehensive tool</i>	Systematic review/meta-analysis	
			Validated data repository (e.g., NCBI, GenBank, PDB)	Example: NCBI and other tools, <i>Individual scientific data, comprehensive tool</i>	Transferable research (e.g., clinical, bench, etc.)	
Types of Outputs	APPLICATION	IMPLEMENTATION	HEALTH MEASURES			
	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools
	Advanced testing of evidence-based research	RPORTER, EUPORTER, RFPs, Patent application (USPTO), etc. provides data, FDA, etc. (e.g., <i>open access data, comprehensive tool</i>)	Drugs to market	FDA approvals, Industry Research	Burden of Disease/Health of Life	
	Advanced testing of evidence-based therapeutic innovation	Class outline (e.g., Phase I trials), RREPORTER (linking publications to clinical trials), EUPORTER, RFPs, FDA Orange Book (e.g., <i>open access data, comprehensive tool</i>)	Determination and implementation of practice guidelines, etc.	NIH research activities (NIH, etc.) (e.g., <i>open access data, comprehensive tool</i>)		
Types of Impacts	Advanced testing of evidence-based preventive intervention and infrastructure	Class outline (e.g., Phase I trials), RREPORTER (linking publications to clinical trials), EUPORTER, RFPs, FDA Orange Book (e.g., <i>open access data, comprehensive tool</i>)	Adoption of evidence-based drugs, etc. and other products	Healthcare costs (e.g., <i>open access data, comprehensive tool</i>)		
	Identification of major public health issues and research risks	ODD (NIH), WHO	Public health campaign	NIH activities (e.g., <i>open access data, comprehensive tool</i>)		
Types of Impacts	PROXIMAL	INTERMEDIATE				
	Indicators	Measurement and assessment tools	Indicators	Measurement and assessment tools		
	Support government policies, and technology use	NIH Budget Office, RFPs, contract research, STAR HETICs, <i>Tool/Innovation</i>	Support private sector activity (e.g., Biotech, Pharma)	FDA approvals (e.g., <i>open access data, comprehensive tool</i>)		
	Create demand for R&D program	Protein structure, RFPs, STAR HETICs, <i>Tool/Innovation</i>	Enhance R&D innovation	NIH Research (e.g., <i>open access data, comprehensive tool</i>)		
Types of Impacts	International collaboration	NIH funding, RREPORTER, STAR HETICs, RFPs	Communication and interpretation of findings across countries and the public	Open-source development of RFPs, etc.		
	Support academic	<i>Tool/Innovation</i> (e.g., <i>open access data, comprehensive tool</i>)	Information of R&D capacity building	<i>Tool/Innovation</i>		
	Developing capacity in the process	<i>Tool/Innovation</i> (e.g., <i>open access data, comprehensive tool</i>)	Support of capacity	<i>Tool/Innovation</i>		
	Generate other collaboration	<i>Tool/Innovation</i> (e.g., <i>open access data, comprehensive tool</i>)				

Charge Element 2: Methods & Strategies

Existing Metrics: Room to Improve



*Charge Element 3: Study Selection***Study Question & Topic Selection**

What topics best communicate and represent NIH's value?

The broad scope of NIH research and the multitude of potential outcomes to be measured pose challenges to assessment efforts. The SMRB is tasked with advising NIH regarding the selection of study topics that are feasible and representative.

– 19 –

VOBR WORKING GROUP June 4, 2013

*Charge Element 3: Study Selection***Goals of Case Study Selection**


- **Illustrate the full spectrum of NIH research, including:**
 - Basic and clinical research
 - Slow and quick time to payoff
 - Successes and “failures”
- **Underscore the importance of investments in basic research**

– 20 –

VOBR WORKING GROUP June 4, 2013


*Charge Element 3: Study Selection***Goals of Case Study Selection** (cont.)**NIH FY 2013 Research Funding**

Total: \$30 billion



– 21 –

VOBR WORKING GROUP June 4, 2013

*Charge Element 3: Study Selection***Goals of Case Study Selection** (cont.)

Goals for Today's Presentations

- Discuss principles and attributes of how to define and assess value
- Learn of opportunities to improve assessments
- Engage experts in ways to assess value of scientific knowledge, public health, and broader societal effects of biomedical research, including:
 - Strengths and gaps of prior studies
 - Landscape of current efforts
 - Outlook for future endeavors
- Discuss the relevance of these findings to NIH

– 23 –

VOBR WORKING GROUP June 4, 2013

Panel Sessions and Roundtable

- **Panel I:** *Assessing the Value of Biomedical Research: Principles, Metrics, Strategies, and Caveats*
- **Panel II:** *Public Health Outputs and Outcomes of Biomedical Research*
- **Panel III:** *Broader Societal Impacts of Biomedical Research*
- **Roundtable Discussion of Value of Biomedical Research Themes**

– 24 –

VOBR WORKING GROUP June 4, 2013

Panel Sessions and VOBR Working Group Deliverables

		DELIVERABLES		
TYPES OF VALUE		Principles and Caveats	Assessment Methods and Strategies	Study Questions and Study Topic Selection
	Scientific	Panel I		
	Public Health	Panel II		
	Societal Impacts	Panel III		
		Roundtable		

– 25 –

VOBR WORKING GROUP June 4, 2013